Avigen, Inc. (NASDAQ: AVGN), a biopharmaceutical company, engages in the development and commercialization of small molecule therapeutics designed to treat serious neurological disorders, including neuropathic pain and opioid addiction and withdrawal. The company’s strategic aim is to complete the requirements of clinical development for each of the candidates in its product pipeline, while seeking opportunities to expand its pipeline through internal research, acquisitions, and in-licensing. For further information, visit the Company’s web site at www.avigen.com.
- 18 years ago
QualityStocks
Avigen, Inc. (NASDAQ: AVGN)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Moves GelrinC Closer to Regulatory and Commercial Milestones
Regentis Biomaterials (NYSE American: RGNT) is advancing its GelrinC hydrogel-based cartilage regeneration technology toward key clinical, regulatory…
-
Wrap Technologies Inc. (NASDAQ: WRAP) Positions Non-Lethal Innovation at the Center of Public Safety Reform
WRAP offerings illustrate a broader industry trend toward building connected ecosystems rather than standalone products.…
-
Brownfield Gold Projects Could Hold an Edge in Today’s Permitting Environment
Disseminated on behalf of Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) and may include paid advertising.…